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Abstract. Background: D-dimer is related to adverse out-
comes in arterial and venous thromboembolic diseases.
Objectives: To evaluate the predictive value of D-dimer
level for stroke, other cardiovascular events, and bleeds,
in patients with atrial fibrillation (AF) treated with oral
anticoagulation with apixaban or warfarin; and to evalu-
ate the relationship between the D-dimer levels at baseline
and the treatment effect of apixaban vs. warfarin. Meth-
ods: In the ARISTOTLE trial, 18 201 patients with AF
were randomized to apixaban or warfarin. D-dimer was
analyzed in 14 878 patients at randomization. The cohort
was separated into two groups; not receiving vitamin K
antagonist (VKA) treatment and receiving VKA treat-
ment at randomization. Results: Higher D-dimer levels
were associated with increased frequencies of stroke or
systemic embolism (hazard ratio [HR] [Q4 vs. Q1] 1.72,
95% confidence interval [CI] 1.14–2.59, P = 0.003),
death (HR [Q4 vs. Q1] 4.04, 95% CI 3.06–5.33) and
major bleeding (HR [Q4 vs. Q1] 2.47, 95% CI 1.77–3.45,
P < 0.0001) in the no-VKA group. Similar results were
obtained in the on-VKA group. Adding D-dimer level to
the CHADS2 score improved the C-index from 0.646 to
0.655 for stroke or systemic embolism, and from 0.598 to
0.662 for death, in the no-VKA group. D-dimer level
improved the HAS-BLED score for prediction of major
bleeds, with an increase in the C-index from 0.610 to
0.641. There were no significant interactions between effi-
cacy and safety of study treatment and D-dimer level.
Conclusion: In anticoagulated patients with AF, the level
of D-dimer is related to the risk of stroke, death, and
bleeding, and adds to the predictive value of clinical risk
scores. The benefits of apixaban were consistent, regard-
less of the baseline D-dimer level.
Keywords: apixaban; atrial fibrillation; D-dimer; risk
assessment; warfarin.
Introduction
Atrial fibrillation (AF) is associated with an increased risk
of stroke and systemic embolism (SEE) and death [1,2].
Oral anticoagulant treatment with vitamin K antagonist
(VKA) reduces the risk of stroke more effectively than
antiplatelet therapy, but less effectively than some of the
newer oral anticoagulants [3–5]. The currently established
tools for balancing the benefits of stroke prevention and
the bleeding risk during anticoagulant treatment are
based on clinical risk scores such as CHADS2/CHA2DS2-
VASc and HAS-BLED [6–10]. As most clinical risk fac-
tors have similar relationships to both thromboembolic
and bleeding events, and reflect vascular disease risk fac-
tors as opposed to thrombus in the left atrial appendage,
the tailoring of treatment to an individual patient is
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challenging, and might be improved by the addition of
information from biomarkers [11–13]. D-dimer is formed
upon degradation of fibrin, and reflects thrombin genera-
tion and fibrin turnover [14]. The D-dimer level is a clini-
cally useful tool for the diagnosis of venous
thromboembolism, is a risk marker for recurrences after
cessation of anticoagulant treatment, and is associated
with thrombotic complications in patients with cancer
[15–17]. D-dimer levels are increased in patients with AF,
and high levels are associated with left atrial appendage
thrombus [18–20]. Warfarin treatment reduces D-dimer
levels, but the relationship between quality of control of
warfarin treatment (i.e. International Normalized Ratio
[INR] levels) and D-dimer level has varied in different
studies [21–23]. Apixaban, an oral direct factor Xa inhibi-
tor, has been found to reduce D-dimer levels in patients
with venous thromboembolism and acute coronary syn-
drome [24,25]. In the ARISTOTLE trial on patients with
AF and at increased risk of stroke, anticoagulant treat-
ment with apixaban as compared with warfarin reduced
the rates of stroke and SEE, all-cause mortality, and
bleeding [5]. In this study, we evaluated D-dimer level as
an independent risk factor for stroke and other non-fatal
and fatal cardiovascular events and for bleeding. We also
assessed the effects of randomized treatment on outcomes
in relation to D-dimer level at baseline.
Patients and methods
The ARISTOTLE trial
The details of the ARISTOTLE trial have been published
previously [5,9]. Briefly, ARISTOTLE was a double-blind,
double-dummy, randomized clinical trial that enrolled
patients with AF and at least one CHADS2 risk factor
for stroke or SEE. Patients were randomly assigned
(1 : 1) to receive either warfarin (target international nor-
malized ratio [INR] of 2.0–3.0) or apixaban (5 mg twice
daily). The number of patients included in the trial was
18 201, and the median follow-up was 1.8 years. The pri-
mary endpoint was stroke or SEE, and the primary safety
outcome was major bleeds according to the classification
of the ISTH [26].
Clinical endpoints and risk factor classification
The endpoints included stroke, defined as a neurologic
deficit that lasted for at least 24 h and subclassified as
ischemic (with or without hemorrhagic conversion), hem-
orrhagic, or uncertain, death from all causes, cardiac
death excluding fatalities caused by bleeding and non-car-
diac causes, and myocardial infarction (MI). Major
bleeding was defined as clinically overt bleeding with a
decrease in hemoglobin level of at least 2 g L1 or trans-
fusion of two or more units of packed red cells, occurring
at a critical site, or resulting in death. Clinically relevant
non-major bleeding was defined as clinically overt bleed-
ing that did not fulfill the criteria for major bleeding but
that led to hospital admission, physician-guided treat-
ment, or a change in the oral antithrombotic treatment.
All clinical events were classified by a blinded clinical
event committee using prespecified criteria [27]. CHADS2,
CHA2DS2-VASc and HAS-BLED scores were calculated
individually for each patient on the basis of the sum of
risk factors present at randomization. Patients were cate-
gorized by CHADS2 according to scores of 0–1, 2, and
≥ 3, by CHA2DS2-VASc according to scores of 0–1, 2, 3,
4, and ≥ 5, and by HAS-BLED according to scores of
0–1, 2, and ≥ 3.
Biochemical analysis
At randomization, blood samples for core laboratory
analyses of prespecified biomarkers were obtained from
14 878 patients. After centrifugation at 2000 9g for 15
min, platelet-poor plasma was stored at  80 °C until
analysis. D-dimer was centrally analyzed with a quantita-
tive method; ELISA (Asserachrome; Stago, Asnieres-
sur-Seine, France) in the Uppsala Clinical Research
Center (UCR) laboratory, Sweden. The reference limit of
normal was ≤ 500 lg L1. The intra-assay coefficient of
variance was 11%.
Statistical analyses
The analyses included the 14 878 patients with available
D-dimer results at baseline before randomization to study
treatment. The median follow-up time was 1.9 years in
the D-dimer cohort. Anticoagulant treatment influences
coagulation activity and D-dimer levels [19]. Therefore,
the patient cohort was stratified into two groups: no
VKA, defined as not treated with oral anticoagulant
agents within the last week prior to randomization or
study entry (n = 6867); and on VKA, defined as treated
with oral anticoagulant treatment within the last 7 days
(n = 7982). In 29 of 14 878 patients, there was no infor-
mation regarding the last dose of anticoagulant treat-
ment, and these patients were therefore excluded from the
analyses. D-dimer levels were compared between VKA
groups by use of the Wilcoxon signed rank test. Demo-
graphics and other baseline characteristics were summa-
rized by the use of frequencies for categorical variables
and median and 25th and 75th percentiles for continuous
variables. For tests among groups, the chi-square test was
used for categorical variables and the Kruskal–Wallis test
was used for continuous variables.
Efficacy analyses included all randomized patients and
all events from randomization until the efficacy cut-off date
(predefined as 30 January 2011). Bleeding analyses were
‘on treatment’, including all randomized patients who
received at least one dose of study drug, and included all
events from receipt of the study drug until 2 days after the
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last dose of the study drug. The incidence rates of the dif-
ferent endpoints were summarized in relation to VKA
treatment, quartiles of D-dimer levels, and CHADS2,
CHA2DS2-VASc or HAS-BLED scores, as outlined above.
The relationships between D-dimer levels and outcomes
were evaluated both in simple and in adjusted Cox regres-
sion analysis. The adjusted analyses included randomized
treatment, and, for efficacy outcomes, the three different
models included CHADS2 score, CHA2DS2-VASc score or
the variables in the score: congestive heart failure, hyper-
tension, age, diabetes mellitus, previous stroke or transient
ischemic attack, previous MI, peripheral arterial occlusive
disease, and female sex for efficacy endpoints. For bleeding
outcomes, the adjusted analyses included randomized treat-
ment, HAS-BLED score or variables in the score: hyper-
tension, age, previous stroke, previous major bleeding and
medication predisposing to bleeding for safety endpoints.
The hazard ratios (HRs) and 95% confidence intervals
(CIs), with the group with the lowest biomarker levels as
reference, were reported. Event rates were reported per 100
patient-years of follow-up. Kaplan–Meier estimates of
cumulative hazard were calculated and plotted.
Treatment effects were compared according to D-dimer
group with a Cox proportional hazard model including
treatment group, CHADS2 or HAS-BLED score,
D-dimer quartile group and treatment by D-dimer inter-
action as covariates. The treatments HRs are reported at
each level of D-dimer, regardless of the significance of
interaction. Adjustment for CHA2DS2-VASc score
yielded similar results (data not shown).
The interaction between VKA treatment and D-dimer
was investigated with a Cox proportional hazard model,
including treatment group, VKA treatment group,
D-dimer quartile group and VKA treatment by D-dimer
interaction as covariates.
The increased discriminative values of adding D-dimer
to models with only CHADS2, CHA2DS2-VASc or HAS-
BLED score and study treatment were investigated by
estimating the C-index for the Cox regression models with
and without the biomarker [28]. In addition, the continu-
ous (category-free) net reclassification improvement index
(NRI) for survival data, as described by Pencina et al.
[28], was calculated for the total group of 14 849 patients,
for the addition of D-dimer to a model with study treat-
ment, baseline VKA treatment and one of CHADS2,
CHA2DS2-VASc or HAS-BLED score. The NRI among
event patients and among non-event patients and the
total NRI were analysed. We performed likelihood ratio
tests to evaluate whether the global model fit improved
after the addition of D-dimer.
All statistical tests were two-tailed and performed at
the 0.05 significance level. Owing to the exploratory nat-
ure of this study, the P-values were not adjusted for mul-
tiple comparisons, and should be interpreted with
caution. The statistics section at UCR conducted the sta-
tistical analyses, using the statistical software package SAS,
version 9.3 for Windows (SAS Institute, Cary, NC, USA)
for all analyses.
Results
Baseline characteristics in relation to D-dimer levels at
baseline
Baseline characteristics are shown in Table 1. The group
with no VKA treatment before randomization had a
higher proportion of females, a higher rate of left ventric-
ular dysfunction and a lower proportion of diabetes mell-
itus than the group receiving VKA treatment at
randomization. Only 0.78% (n = 116) of the patients had
a history of cancer. No difference was found regarding
previous stroke or CHADS2/CHA2DS2-VASc score. The
median D-dimer level was 528 lg L1 (interquartile
range 335–878 lg L1) in the total cohort at baseline,
and there was no difference in D-dimer levels between the
apixaban and warfarin groups. The D-dimer levels in the
no-VKA and on-VKA groups are shown in Table 2.
Higher D-dimer levels were associated with increased age,
female sex, left ventricular dysfunction and atherosclerotic
disease in both the no-VKA group and the on-VKA
group at randomization (Tables 3 and 4).
D-dimer levels at baseline in relation to thromboembolic
events and death
In the D-dimer cohort, a total of 397 patients (1.40% per
year) experienced a stroke/SEE, and 1075 (3.69% per
year) died; of these, 547 (1.88% per year) died of cardiac
causes, and 150 (0.52% per year) suffered an MI. D-dimer
levels at baseline were associated with rate of stroke/SEE
in both the no-VKA group and the on-VKA group
(Fig. 1). In the no-VKA group, the stroke/SEE rate ran-
ged from 1.11% per year in Q1 (D-dimer ≤ 423 lg L1)
to 1.90% per year in Q4 (D-dimer > 1123 lg L1)
(HR [Q4 vs. Q1] 1.72, 95% CI 1.14–2.59, P = 0.003 for
association with D-dimer levels). Similar results were
found in the on-VKA group, with stroke/SEE rates of
0.74% per year in Q1 (D-dimer ≤ 289 lg L1) and 1.32%
per year in Q4 (D-dimer > 690 lg L1) (HR [Q4 vs.
Q1] 1.79, 95% CI 1.13–2.84, P = 0.027). After adjustment
for CHADS2 score, the association between D-dimer lev-
els and stroke/SEE rate persisted in the no-VKA group
but not in the on-VKA group (Fig. 2). Adjustment for
CHA2DS2-VASc score attenuated the association between
D-dimer levels and stroke/SEE rate. Higher D-dimer levels
were also related to higher rates of total death (HR [Q4
vs. Q1] 4.04, 95% CI 3.06–5.33, P < 0.0001) and cardiac
death (HR 2.79, 95% CI 1.97–3.94, P < 0.0001) in the
no-VKA group. Similar results were obtained in the on-
VKA group (total death HR [Q4 vs. Q1] 5.50,
95% CI 4.00–7.57, P < 0.0001; cardiac death HR 5.83,
95% CI 3.62–9.39, P < 0001). These results persisted after
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adjustment for CHADS2 score and study treatment in both
the no-VKA group and the on-VKA group (Fig. 2), and
also after adjustment for CHA2DS2-VASc score or the
variables included in the score (data not shown). The MI
rate was low, and no association was found with D-dimer
levels in the no-VKA group. In the on-VKA group, the MI
rate ranged from 0.35% per year in Q1 to 1.00% per year
in Q4 (HR [Q4 vs. Q1] 2.50, 95% CI 1.34–4.68, P = 0.002
after adjustment for CHADS2 score and treatment)
(Fig. 2). These results persisted after adjustment for
CHA2DS2-VASc score or the variables included in the
score (data not shown).
Table 1 Baseline characteristics in the no-vitamin K antagonist (VKA) and on-VKA groups
No VKA (n = 6867) On VKA (n = 7982) Total (n = 14 878)
Age in years (mean  SD) 68.5  9.8 69.4  9.3 69.0  9.6
Female sex, no. (%) 2666 (38.8) 2618 (32.8) 5291 (35.6)
Male sex, no. (%) 4201 (61.2) 5364 (67.2) 9587 (64.4)
AF, persistent or permanent, no. (%) 5708 (83.1) 6889 (86.3) 12622 (84.9)
Calculated CrCl (mL min1), median (Q1–Q3) 72.6 (56.0–92.9) 75.5 (57.5–98.0) 74.2 (56.8–95.4)
Risk factors, no. (%)
Congestive HF/LVEF ≤ 40% 2727 (39.7) 2619 (32.8) 5353 (36.0)
Age ≥ 75 years 1978 (28.8) 2561 (32.1) 4553 (30.6)
Hypertension 6087 (88.6) 6923 (86.7) 13 033 (87.6)
Diabetes mellitus 1587 (23.1) 2078 (26.0) 3676 (24.7)
Prior stroke or TIA 1253 (18.2) 1531 (19.2) 2788 (18.7)
Prior MI 842 (12.3) 1066 (13.4) 1914 (12.9)
PAOD 320 (4.7) 406 (5.1) 727 (4.9)
CHADS2 score, no. (%)
0–1 2266 (33.0) 2769 (34.7) 5046 (33.9)
2 2505 (36.5) 2860 (35.8) 5371 (36.1)
≥ 3 2096 (30.5) 2353 (29.5) 4461 (30.0)
CHA2DS2-VASc score, no. (%)
0–1 598 (8.7) 699 (8.8) 1299 (8.7)
2 1435 (20.9) 1658 (20.8) 3099 (20.8)
3 1737 (25.3) 2122 (26.6) 3863 (26.0)
4 1528 (22.3) 1758 (22.0) 3294 (22.1)
≥ 5 1569 (22.8) 1745 (21.9) 3323 (22.3)
HAS-BLED score, no. (%)
0–1 3150 (45.9) 2351 (29.5) 5503 (37.0)
2 2507 (36.5) 3070 (38.5) 5590 (37.6)
≥ 3 1210 (17.6) 2561 (32.1) 3785 (25.4)
Medical treatment at baseline, no. (%)
Subcutaneous/intravenous heparin within the last week* 454 (6.6) 269 (3.4) 723 (4.9)
Aspirin 3622 (44.0) 1566 (19.6) 4599 (30.9)
Clopidogrel 160 (2.3) 102 (1.3) 262 (1.8)
ACE inhibitor or ARB 2014 (29.3) 2313 (29.0) 4337 (29.2)
b-Blocking agent 4145 (60.4) 5248 (65.7) 9415 (63.3)
Calcium channel blocking agent 1931 (28.1) 2599 (32.6) 4539 (30.5)
Amiodarone 948 (13.8) 763 (9.6) 1712 (11.5)
Digoxin 2165 (31.5) 2654 (33.2) 4830 (32.5)
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CrCl, creatinine clearance; HF/LVEF, heart
failure/left ventricular ejection fraction; MI, myocardial infarction; PAOD, peripheral arterial occlusive disease; SD, standard deviation; TIA,
transient ischemic attack. *At least one dose of heparin within the last week.
Table 2 Description of the D-dimer levels at baseline in the no-vitamin K antagonist (VKA) and on-VKA groups
D-dimer No-VKA group (n = 6867) On-VKA group (n = 7982) P-value
Mean (lg L1) (SD) 1053 (1193) 649 (806) < 0.0001
Median (lg L1) (interquartile range) 665 (423–1123) 432 (289–690) < 0.0001
10th–90th percentiles (lg L1) 299–2097 206–1149
Range (lg L1) 54–7000 6–7000
D-dimer > 500 lg L1 (%) 66 42
SD, standard deviation.
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D-dimer levels in relation to CHADS2/CHA2DS2-VASc score
for risk stratification of thromboembolic events and death
The annual rates of stroke/SEE and death increased both
with CHADS2 score and with D-dimer levels in the
no-VKA group, and a similar trend was found in the on-
VKA group. The C-index values for D-dimer level alone
were 0.587 and 0.567 in the no-VKA group and the on-
VKA group, respectively (Table S1). After addition of
D-dimer level to the CHADS2 score, the C-index
increased from 0.600 to 0.618 in the on-VKA group. The
C-index was higher in the no-VKA group, where the
event rate was higher, but the improvement with addition
of D-dimer level was somewhat smaller, the C-index
increasing from 0.646 to 0.655. The model improved sig-
nificantly only in the no-VKA group. With regard to the
prediction of death, the C-index values for D-dimer level
alone were 0.636 and 0.670 in the no-VKA group and the
on-VKA group, respectively. With regard to prediction of
cardiovascular death, the C-index for D-dimer level was
higher in the on-VKA group (0.675) than in the no-VKA
group (0.600). The addition of D-dimer level to the
CHADS2 score improved the C-index most in the on-
VKA group, from 0.588 to 0.685, but also in the no-
VKA group, from 0.598 to 0.662. When D-dimer level
was added to the CHA2DS2-VASc score, a similar
improvement in the prediction of stroke/SEE and death
was noted. The NRI was 11% for stroke/SEE: 18%
among event patients, and  7% among non-event
patients. The NRI was 46% for death: 24% among event
patients, and 22% among non-event patients (Table S1).
D-dimer levels in relation to efficacy of randomized
treatment for thromboembolic events
The benefits of apixaban as compared with warfarin
regarding stroke/SEE were similar through D-dimer quar-
tiles, both in the no-VKA group and in the on-VKA
group. Accordingly, higher D-dimer levels tended to be
associated with a larger absolute gain in stroke/SEE bene-
fit with apixaban than with warfarin, even after adjust-
ments for CHADS2 score (Fig. 3). Also the benefits with
apixaban compared to warfarin regarding total death and
cardiac death were similar over the range of D-dimer
levels (Fig. 3).
D-dimer levels at baseline and bleeding outcomes
Major bleeds occurred in 647 patients (2.61% per year) and
1276 patients had a major/clinically relevant non-major
Table 3 Baseline characteristics according to D-dimer quartiles in the no-vitamin K antagonist group
D-dimer (lg L1)
≤ 423 (n = 1719) > 423–665 (n = 1718) > 665–1123 (n = 1717) > 1123 (n = 1713) P-value
Age in years (mean  SD) 62.9 (9.54) 67.7 (8.91) 70.5 (8.80) 72.8 (9.16) < 0.0001
Female sex, no. (%) 480 (27.9) 673 (39.2) 743 (43.3) 770 (45.0) < 0.0001
Male sex, no. (%) 1239 (72.1) 1045 (60.8) 974 (56.7) 943 (55.0)
AF, persistent or permanent, no. (%) 1393 (81.0) 1418 (82.6) 1426 (83.1) 1471 (85.9) < 0.0001
Risk factors, no. (%)
Congestive HF/LVEF ≤ 40% 635 (36.9) 679 (39.5) 681 (39.7) 732 (42.7) 0.0071
Age ≥ 75 years 180 (10.5) 397 (23.1) 594 (34.6) 807 (47.1) < 0.0001
Hypertension 1527 (88.8) 1538 (89.5) 1522 (88.6) 1500 (87.6) 0.34
Diabetes mellitus 396 (23.0) 426 (24.8) 406 (23.6) 359 (21.0) 0.0576
Prior stroke or TIA 288 (16.8) 307 (17.9) 307 (17.9) 351 (20.5) 0.0341
Prior MI 173 (10.1) 209 (12.2) 233 (13.6) 227 (13.3) < 0.0001
PAOD 49 (2.9) 71 (4.1) 76 (4.4) 124 (7.2) < 0.0001
CHADS2 score, no. (%)
0–1 755 (43.9) 574 (33.4) 536 (31.2) 401 (23.4) < 0.0001
2 560 (32.6) 648 (37.7) 632 (36.8) 665 (38.8)
≥ 3 404 (23.5) 496 (28.9) 549 (32.0) 647 (37.8)
CHA2DS2-VASc score, no. (%)
0–1 302 (17.6) 138 (8.0) 95 (5.5) 63 (3.7) < 0.0001
2 530 (30.8) 363 (21.1) 312 (18.2) 230 (13.4)
3 384 (22.3) 490 (28.5) 463 (27.0) 400 (23.4)
4 271 (15.8) 370 (21.5) 406 (23.6) 481 (28.1)
≥ 5 232 (13.5) 357 (20.8) 441 (25.7) 539 (31.5)
HAS-BLED score, no. (%)
0–1 987 (57.4) 787 (45.8) 728 (42.4) 648 (37.8) < 0.0001
2 520 (30.3) 655 (38.1) 650 (37.9) 682 (39.8)
≥ 3 212 (12.3) 276 (16.1) 339 (19.7) 383 (22.4)
AF, atrial fibrillation; HF/LVEF, heart failure/left ventricular ejection fraction; MI, myocardial infarction; PAOD, peripheral arterial occlusive
disease; SD, standard deviation; TIA, transient ischemic attack. P-value by chi-square test for categorical variables and Kruskal–Wallis test for
continuous variables.
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bleed (5.05% per year) during the median follow-up of
1.9 years. Higher D-dimer levels were significantly associ-
ated with increased risk of both major and major/clinically
relevant non-major bleeds, regardless of VKA treatment sta-
tus at baseline (Fig. 4). In the no-VKA group, the rate of
major bleeds ranged from 1.61% per year in Q1 (D-dimer <
423 lg L1) to 2.45% per year in Q4 (D-dimer > 1123 lg
L1) (HR [Q4 vs. Q1] 2.17, 95% CI 1.55–3.04, P < 0.0001
after adjustment for HAS-BLED score). Similar results were
obtained in the on-VKA group (HR [Q4 vs. Q1] 1.97,
95% CI 1.44–2.69, P < 0.0001) (Fig. 2). Similar results
were also found after adjustment for the variables included
in the score (data not shown).
D-dimer levels in relation to HAS-BLED score for risk
stratification of bleeding
The annual risk of major bleeds increased with both
HAS-BLED score and D-dimer quartiles. In the no-VKA
group, the rates of major bleeds were 1.16% per year in
the group with HAS-BLED 0–1 and D-dimer Q1, and
4.94% per year in the group with HAS-BLED ≥ 3 and
D-dimer Q4. Similar results were obtained in the on-
VKA group: 1.09% per year in the group with
HAS-BLED 0–1 and D-dimer Q1, and 5.03% per year in
the group with HAS-BLED ≥ 3 and D-dimer Q4. The
C-index values for D-dimer for major bleeds were 0.621
and 0.587 in the no-VKA group and the on-VKA group,
respectively. Adding D-dimer level to the HAS-BLED
score improved the predictive model for major bleeds
from 0.610 to 0.641 in the no-VKA group and from
0.618 to 0.635 in the on-VKA group. The NRI was 28%
for major bleed: 5% among event patients, and 23%
among non-event patients (Table S1).
D-dimer levels in relation to efficacy of randomized
treatment for bleeding events
There was no significant interaction between D-dimer lev-
els and randomized treatment with respect to bleeding
events. Even after adjustment for HAS-BLED score and
VKA status at randomization, apixaban treatment was
associated with consistent reductions in the rates of major
bleeds and major bleeds/clinically relevant non-major
bleeds over the range of D-dimer levels. In the no-VKA
group, the rates of major bleeds were 3.21% per year in
the apixaban-randomized patients and 4.92% per year
in the warfarin-randomized patients in Q4
(D-dimer > 1123 lg L1) (HR 0.66, 95% CI 0.45–0.97).
In the on-VKA group, the HR for apixaban vs. warfarin
Table 4 Baseline characteristics according to D-dimer quartiles in the on-vitamin K antagonist group
D-dimer (lg L1)
≤ 289 (n = 2004) > 289–432 (n = 1990) > 432–690 (n = 1995) > 690 (n = 1993) P-value
Age in years (mean  SD) 64.0 (9.13) 68.8 (8.54) 71.6 (8.18) 73.3 (8.78) < 0.0001
Female sex, no. (%) 517 (25.8) 650 (32.7) 743 (37.2) 708 (35.5) < 0.0001
Male sex, no. (%) 1487 (74.2) 1340 (67.3) 1252 (62.8) 1285 (64.5)
AF, persistent or permanent, no. (%) 1722 (85.9) 1693 (85.1) 1727 (86.6) 1747 (87.7) 0.1109
Risk factors, no. (%)
Congestive HF/LVEF ≤ 40% 591 (29.5) 604 (30.4) 654 (32.8) 770 (38.6) < 0.0001
Age ≥ 75 years 252 (12.6) 539 (27.1) 796 (39.9) 974 (48.9) < 0.0001
Hypertension 1715 (85.6) 1734 (87.1) 1747 (87.6) 1727 (86.7) 0.2813
Diabetes mellitus 515 (25.7) 535 (26.9) 516 (25.9) 512 (25.7) 0.7972
Prior stroke or TIA 344 (17.2) 398 (20.0) 371 (18.6) 418 (21.0) 0.0136
Prior MI 205 (10.2) 261 (13.1) 279 (14.0) 321 (16.1) < 0.0001
PAOD 62 (3.1) 69 (3.5) 113 (5.7) 162 (8.1) < 0.0001
CHADS2 score, no. (%)
0–1 938 (46.8) 738 (37.1) 596 (29.9) 497 (24.9) < 0.0001
2 654 (32.6) 668 (33.6) 781 (39.1) 757 (38.0)
≥ 3 412 (20.6) 584 (29.3) 618 (31.0) 739 (37.1)
CHA2DS2-VASc score, no. (%)
0–1 379 (18.9) 164 (8.2) 86 (4.3) 70 (3.5) < 0.0001
2 598 (29.8) 418 (21.0) 375 (18.8) 267 (13.4)
3 505 (25.2) 573 (28.8) 545 (27.3) 499 (25.0)
4 293 (14.6) 432 (21.7) 470 (23.6) 563 (28.2)
≥ 5 229 (11.4) 403 (20.3) 519 (26.0) 594 (29.8)
HAS-BLED score, no. (%)
0–1 840 (41.9) 587 (29.5) 452 (22.7) 472 (23.7) < 0.0001
2 715 (35.7) 770 (38.7) 812 (40.7) 773 (38.8)
≥ 3 449 (22.4) 633 (31.8) 731 (36.6) 748 (37.5)
AF, atrial fibrillation; HF/LVEF, heart failure/left ventricular ejection fraction; MI, myocardial infarction; PAOD, peripheral arterial occlusive
disease; SD, standard deviation; TIA, transient ischemic attack. P-value by chi-square test for categorical variables and Kruskal–Wallis test for
continuous variables.
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was 0.57 (95% CI 0.39–0.82) in D-dimer Q4 (D-dimer >
690 lg L1) (Fig. 3).
Discussion
This study has verified that D-dimer levels are increased in
patients with AF and at least one risk factor for stroke,
increase with age, female sex, heart failure, and atheroscle-
rotic diseases. Increasing D-dimer level was gradually
related to the rates of stroke/SEE, all-cause death, cardiac
death, and major bleeds. Ongoing treatment with warfarin
was associated with lower D-dimer levels, but the relation-
ships with patient characteristics were observed both in
patients without and those with anticoagulant treatment.
The predictive values of D-dimer level alone for death and
major bleeds were higher than those of the clinical risk
scores. Adding D-dimer to the CHADS2, CHA2DS2-VASc
and HAS-BLED scores improved the prediction of throm-
boembolic events and bleeds, respectively. The benefits of
apixaban and those of warfarin regarding stroke/SEE, all-
cause death, cardiac death and bleeds were not significantly
different through the range of D-dimer levels.
D-dimer levels and CHADS2/CHA2DS2-VASc scores
In the present study, high D-dimer levels were related to
increased risks of stroke/SEE and all-cause death, both
total death and cardiac death. In clinical practice, risk
stratification of the AF patient is commonly performed
with risk scores, such as CHADS2/CHA2DS2-VASc,
based on clinical features. The CHADS2 score was pri-
marily developed to estimate the risk of stroke in patients
without anticoagulant treatment, in order to support deci-
sion-making for this therapy [6]. Today, the CHADS2
score has also been found to be predictive of stroke and
of death in patients with anticoagulant treatment [10]. In
the present study, D-dimer added predictive value to the
CHADS2 and CHA2DS2-VASc scores for stroke/SEE,
and even more value concerning death. D-dimer level
alone had an even higher predictive value for death and
cardiovascular death than the clinical risk scores, whether
or not patients were receiving warfarin treatment. The
predictive value was most pronounced in the on-VKA
group, indicating that patients with high D-dimer levels
despite anticoagulant treatment have a more advanced
underlying disease that is not identified by the clinical risk
scores. Measurement of the D-dimer level is widely avail-
able as a routine method in most hospitals. Therefore, its
inclusion in a risk stratification tool for patients with AF
might be considered. However, in the real-world environ-
ment, there are many different methods for measuring
D-dimer levels and fairly large variations in the results,
including the influences of preanalytic errors at blood
sampling. Therefore, the clinical usefulness of a measure-
ment of D-dimer level is still questionable, even though it
is recommended as a tool for risk assessment in the set-
ting of venous thromboembolism [16].
D-dimer and risk of bleeding
Increased D-dimer levels have been associated with bleed-
ing and mortality risk in patients with intracerebral hem-
orrhage and cancer [29–31]. The D-dimer level reflects the
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Fig. 1. Cumulative hazard rates for the primary endpoint stroke or
systemic embolism (SEE) by D-dimer quartiles at baseline before
randomization to apixaban or warfarin study treatment. (A) No-
vitamin K antagonist (VKA) group. (B) On-VKA group. Groups 1,
2, 3 and 4 represent D-dimer quartiles 1, 2, 3 and 4, respectively.
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sum of thrombin generation and endogenous fibrin turn-
over, and may be a marker for increased fibrinolytic
activity [32,33]. However, in clinical practice the risk of
bleeding is estimated from clinical history and patient
characteristics, and a perceived increased bleeding risk is
often used as a reason to withhold anticoagulant treat-
ment in AF patients [34]. The HAS-BLED score can be
evaluated in AF patients both with and without anticoag-
ulant treatment, and predicts the risk of bleeding [8,35].
In the present study, increased D-dimer levels were
strongly related to the frequency of major and clinically
significant non-major bleeds, and added predictive value
to the HAS-BLED score to improve bleeding risk stratifi-
cation. The predictive value of D-dimer level alone for
major bleeds was most pronounced in patients who had
no experience of anticoagulant treatment. In a clinical set-
ting, where the bleeding risk has to be evaluated before
initiation of anticoagulant treatment, D-dimer seems to
1                          
Lower risk          Higher risk
Stroke/systemic embolism, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Stroke/systemic embolism, on VKA
≤ 289
> 289–432
> 432–690
> 690
Death, no VKA
≤ 423
> 423–665
> 665–1123
>1123
Death, on VKA
≤ 289
> 289–432
> 432–690
> 690
Cardiac death, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Cardiac death, on VKA
≤ 289
> 289–432
> 432–690
> 690
Myocardial infarction, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Myocardial infarction, on VKA
≤ 289
> 289–432
> 432–690
> 690
Major bleed, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Major bleed, on VKA
≤ 289
> 289–432
> 432–690
> 690
Major bleed/CS non-major bleed, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Major bleed/CS non-major bleed, on VKA
≤ 289
> 289–432
> 432–690
> 690
Outcome 
D-dimer level (µg L–1)
1719
1718
1717
1713
2004
1990
1995
1993
1719
1718
1717
1713
2004
1990
1995
1993
1719
1718
1717
1713
2004
1990
1995
1993
1719
1718
1717
1713
2004
1990
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1993
1716
1711
1714
1708
2000
1987
1993
1991
1716
1711
1714
1708
2000
1987
1993
1991
Number 
of Patients
37 (1.11)
51 (1.55)
72 (2.24)
60 (1.90)
29 (0.74)
43 (1.13)
52 (1.38)
49 (1.32)
63 (1.85)
95 (2.80)
175 (5.28)
243 (7.49)
45 (1.13)
84 (2.17)
130 (3.35)
235 (6.20)
44 (1.29)
50 (1.47)
113 (3.41)
117 (3.61)
20 (0.50)
38 (0.98)
53 (1.37)
111 (2.93)
11 (0.33)
13 (0.39)
15 (0.46)
18 (0.57)
14 (0.35)
13 (0.34)
27 (0.71)
37 (1.00)
50 (1.61)
64 (2.15)
88 (3.08)
109 (4.02)
60 (1.62)
79 (2.23)
98 (2.83)
123 (3.74)
109 (3.58)
129 (4.41)
150 (5.36)
178 (6.70)
135 (3.71)
159 (4.58)
187 (5.54)
224 (7.00)
Events
% per year
0.0302
1.30 (0.85–1.98)
1.79 (1.20–2.67)
1.42 (0.94–2.15)
0.1292
1.43 (0.89–2.29)
1.69 (1.07–2.67)
1.54 (0.96–2.45)
< 0.0001
1.43 (1.04–1.97)
2.62 (1.97–3.51)
3.58 (2.71–4.74)
< 0.0001
1.82 (1.27–2.62)
2.72 (1.94–3.83)
4.83 (3.50–6.67)
< 0.0001
1.08 (0.72–1.62)
2.41 (1.70–3.43)
2.45 (1.72–3.47)
< 0.0001
1.84 (1.07–3.17)
2.48 (1.48–4.16)
5.04 (3.11–8.16)
0.7844
1.11 (0.49–2.48)
1.24 (0.57–2.72)
1.45 (0.68–3.10)
0.0017
0.91 (0.43–1.95)
1.86 (0.97–3.56)
2.50 (1.34–4.68)
< 0.0001
1.24 (0.86–1.80)
1.71 (1.21–2.43)
2.17 (1.55–3.04)
< 0.0001
1.24 (0.88–1.73)
1.50 (1.08–2.07)
1.97 (1.44–2.69)
0.0004
1.15 (0.89–1.49)
1.35 (1.06–1.74)
1.63 (1.28–2.08)
< 0.0001
1.14 (0.90–1.43)
1.33 (1.07–1.67)
1.67 (1.35–2.08)
HR (95% CI) 
Q group 1 
as reference
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Effect of 
biomarker level
0.3     0.5  0.7 3 5 7 9
Fig. 2. The effect of D-dimer quartiles on study endpoints in the no-vitamin K antagonist (VKA) group and the on-VKA group. A Cox pro-
portion model was used, with biomarker level, CHADS2/HAS-BLED score and randomized treatment as covariates. CI, confidence interval;
CS, clinically significant; HR, hazard ratio.
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be a better tool than HAS-BLED score, which includes
risk factors such as previous experience of warfarin.
D-dimer levels and benefit of apixaban
Apixaban was superior to warfarin regarding the risk of
stroke and reduced the frequency of bleeding in the
ARISTOTLE trial [5]. The relative benefits of apixaban
vs. warfarin have been shown consistently across all
CHADS2, CHA2DS2-VASc and HAS-BLED scores, even
though the relative risk reduction for intracranial bleed-
ing tended to be higher in patients with a HAS-BLED
score of ≥ 3 [9]. The relative benefits of apixaban vs.
warfarin were not significantly different between D-dimer
quartiles.
Limitations
The cut-off of D-dimer level for use in risk stratification in
patients with AF has not been defined. In this study, we
used the quartiles of D-dimer, and the optimal D-dimer level
in AF has to be further investigated and prospectively vali-
dated. The INR value in the on-VKA group before random-
ization and the percent time in therapeutic INR range before
randomization to study treatment were not known, and their
relationships with D-dimer levels could not be estimated.
Conclusion
In conclusion, a high D-dimer level is associated with
increased risks of stroke, death, and bleeding, and has
0.1                  0.3      0.5  0.7                         3        5     71
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> 432–690
> 690
Cardiac death, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Cardiac death, on VKA
≤ 289
> 289–432
> 432–690
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46 (2.83)
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62 (3.99)
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Apixaban
Events (% per year)
18 (1.10)
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13 (0.64)
21 (1.09)
25 (1.34)
29 (1.52)
25 (1.49)
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100 (6.04)
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22 (1.07)
45 (2.29)
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18 (1.07)
26 (1.62)
62 (3.74)
62 (3.88)
8 (0.39)
21 (1.07)
31 (1.62)
60 (3.08)
8 (0.49)
4 (0.25)
8 (0.49)
10 (0.64)
7 (0.34)
9 (0.46)
16 (0.86)
16 (0.84)
32 (2.10)
35 (2.51)
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1.08 (0.60–1.97)
1.03 (0.60–1.78)
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0.85 (0.57–1.26)
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0.90 (0.70–1.16)
1.13 (0.63–2.03)
0.90 (0.58–1.38)
0.91 (0.64–1.28)
1.01 (0.78–1.31)
1.41 (0.77–2.57)
0.83 (0.48–1.45)
0.82 (0.57–1.19)
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0.52 (0.37–0.75)
0.80 (0.58–1.09)
0.81 (0.61–1.08)
0.63 (0.49–0.83)
HR (95% CI) P-value for
interaction
Fig. 3. The efficacy of apixaban vs. warfarin for quartiles of D-dimer levels at baseline separated into the group with no vitamin K antagonist
(VKA) treatment and the group receiving VKA treatment before randomization to study treatment. A Cox proportion model was used, with
biomarker level, CHADS2/HAS-BLED score, treatment and interaction between treatment and biomarker level as covariates. CI, confidence
interval; CS, clinically significant; HR, hazard ratio.
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an additional predictive value to clinical risk scores in
patients with AF. There was no interaction between the
D-dimer level at entry and the benefits of apixaban
vs. warfarin for reduction of stroke, mortality, and
bleeding.
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Fig. 4. Cumulative hazard rates of major bleeds in relation to
D-dimer quartiles at baseline before randomization to apixaban or
warfarin study treatment. (A) No-vitamin K antagonist (VKA)
group. (B) On-VKA group. Groups 1, 2, 3 and 4 represent D-dimer
quartiles 1, 2, 3 and 4, respectively.
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